"These studies remind us that most new #cancer drugs are of marginal benefit at best, despite their immense cost"—@RichardLehman1 @JAMAInternalMed https://t.co/WschOhcRt0 spot on re:
Accelerated approval @bishalgyawali @akesselheim
Surrogate endpoints @IamEmchee @VPrasadMDMPH pic.twitter.com/DMrThdLGum— Eric Topol (@EricTopol) May 28, 2019
No comments:
Post a Comment